Quick Answer
Propanc Biopharma, Inc. reported Operating Income of -$57.28 million for fiscal year 2025.
Propanc Biopharma, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$57.28M | -3628.9% |
| 2024 | -$1.54M | +13.5% |
| 2023 | -$1.78M | +10.8% |
| 2022 | -$1.99M | -9.9% |
| 2021 | -$1.81M | +48.1% |
| 2020 | -$3.49M | -33.6% |
| 2019 | -$2.61M | +34.0% |
| 2018 | -$3.96M | +31.0% |
| 2017 | -$5.74M | +16.8% |
| 2016 | -$6.90M | -304.4% |
| 2015 | -$1.71M | -124.1% |
| 2014 | -$761.2K | +44.1% |
| 2013 | -$1.36M | +88.2% |
| 2012 | -$11.59M | -418.5% |
| 2011 | -$2.24M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$3.65M | -1612.8% | +21.8% |
| September 30, 2025 | -$4.67M | -1507.2% | +91.2% |
| March 31, 2025 | -$53.13M | -12523.6% | -24798.4% |
| December 31, 2024 | -$213.4K | +51.3% | +26.6% |
| September 30, 2024 | -$290.8K | +30.3% | +30.9% |
| March 31, 2024 | -$420.9K | -9.0% | +3.9% |
| December 31, 2023 | -$438.1K | +28.0% | -5.0% |
| September 30, 2023 | -$417.2K | +27.2% | -8.0% |
- Propanc Biopharma, Inc. showed a decrease of -3628.9% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, Propanc Biopharma, Inc.’s operating income has declined by 2462.4% (from -$2.24 million to -$57.28 million).
- The most recent figure is from Propanc Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: